Specific recognition of HOM-MEL-40/SSX2-derived p103-111 pulsed targets by p103-111 stimulated T-cells from patients with HOM-MEL-40/SSX2 positive breast.

Slides:



Advertisements
Similar presentations
Volume 17, Issue 9, Pages (September 2015)
Advertisements

Supplementary Figure 3 Antigen-specific responses are enhanced by stimulation in an in vitro stimulation (IVS) assay, as well as with stimulation using.
T-cell responses associated with neonatal alloimmune thrombocytopenia: isolation of HPA-1a–specific, HLA-DRB3*0101–restricted CD4+ T cells by Maria Therese.
WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell–depleted hematopoietic stem cell transplantation and.
Melanoma donor (MD) NK cells are functionally impaired/exhausted.
سرطان الثدي Breast Cancer
Volume 19, Issue 12, Pages (December 2011)
Depletion of Alloreactive Donor T Lymphocytes by CD95-Mediated Activation-Induced Cell Death Retains Antileukemic, Antiviral, and Immunoregulatory T Cell.
Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators by Rikke Bæk Sørensen, Sine Reker Hadrup, Inge Marie Svane, Mads Christian.
A Promiscuous Survivin-Derived T-Cell Epitope Restricted to the HLA-A3 Super-Type Alleles  Niels Junker, Shamaila Munir, Pia Kvistborg, Per thor Straten,
Expansion and isolation of NY-ESO-1–specific T cell clones.
Volume 140, Issue 2, Pages e1 (February 2011)
Patient T cells recognise a SMAD4V370A-containing neoepitope presented by autologous cancer cells. Patient T cells recognise a SMAD4V370A-containing neoepitope.
CMV-, EBV- and ADV-Specific T Cell Immunity: Screening and Monitoring of Potential Third-Party Donors to Improve Post-Transplantation Outcome  Cinja Sukdolak,
Volume 149, Issue 6, Pages e2 (November 2015)
HLA-DPB1 Mismatching Results in the Generation of a Full Repertoire of HLA-DPB1- Specific CD4+ T Cell Responses Showing Immunogenicity of all HLA-DPB1.
ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1–restricted CD8+ T-cell epitopes by Lorena Passoni, Antonio Scardino, Carla.
Promiscuity of the AlloHLA-A2 Restricted T Cell Repertoire Hampers the Generation of Minor Histocompatibility Antigen-specific Cytotoxic T Cells across.
CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib–associated renal carcinoma antigens with ubiquitous or restricted.
Mature dendritic cells pulsed with freeze–thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4+ and CD8+ T lymphocyte.
Impact of clonal competition for peptide-MHC complexes on the CD8+ T-cell repertoire selection in a persistent viral infection by Katherine K. Wynn, Zara.
Longitudinal dynamics of antigen-specific CD8+cytotoxic T lymphocytes following primary Epstein-Barr virus infection by Mandvi Bharadwaj, Scott R. Burrows,
Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients by Raffaella.
Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma by Carmen Choi, Mathias Witzens, Marianna.
Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo by Suzanne M. McGoldrick, Marie E. Bleakley,
Volume 133, Issue 4, Pages (October 2007)
Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses by Cagan Gurer, Till.
Cytomegalovirus-Specific Cytotoxic T Lymphocytes Can Be Efficiently Expanded from Granulocyte Colony-Stimulating Factor–Mobilized Hemopoietic Progenitor.
Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia by Jochen Greiner, Yoko Ono, Susanne.
Application of the ELISPOT assay to the characterization of CD8+ responses to Epstein-Barr virus antigens by Jie Yang, Victor M. Lemas, Ian W. Flinn, Chris.
Induction of chronic lymphocytic leukemia (CLL)–specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells by Martin R. Müller,
Recovery of Varicella-Zoster Virus–Specific T Cell Immunity after T Cell–Depleted Allogeneic Transplantation Requires Symptomatic Virus Reactivation 
Fig. 6. PVSRIPO oncolysate–pulsed DCs generate tumor antigen–specific CTL immunity in vitro. PVSRIPO oncolysate–pulsed DCs generate tumor antigen–specific.
Volume 134, Issue 4, Pages (April 2008)
Christian Möbs, Thomas Schmidt  Journal of Investigative Dermatology 
Induction of T-Cell Responses against Cutaneous T-Cell Lymphomas Ex Vivo by Autologous Dendritic Cells Transfected with Amplified Tumor mRNA  Xiao Ni,
Volume 127, Issue 3, Pages (September 2004)
Tetramer staining performed to determine frequencies of epitope-specific T cells after clearance of HPV16 infection but prior to isolation of T-cell clones.
A comparison of gene transfer and antigen-loaded dendritic cells for the generation of CD4+ and CD8+ cytomegalovirus-specific T cells in HLA-A2+ and HLA-A2−
Volume 13, Issue 2, Pages (February 2006)
Melanoma Inhibitor of Apoptosis Protein (ML-IAP) Specific Cytotoxic T Lymphocytes Cross-React with an Epitope from the Auto-Antigen SS56  Rikke Bæk Sørensen,
Modular Three-component Delivery System Facilitates HLA Class I Antigen Presentation and CD8+ T-cell Activation Against Tumors  Benjamin J Umlauf, Chin-Ying.
Virus-specific T cell responses are detected in all MERS survivors.
Mads Hald Andersen, Jürgen C. Becker, Per thor Straten 
Volume 24, Issue 6, Pages (June 2016)
Fig. 3. Reporter assay for the RS-ATL8 reporter cell line against shrimp extracts (A, B) RS-ATL8 cells were sensitized overnight with diluted pooled sera.
IFN-γ–producing cells in the spleen and lungs postimmunization.
PD-1 blockade enhances T-cell function.
Molecular Therapy - Oncolytics
CD8 T cell memory alters the immune profile in enhanced HLH without altering viral load. CD8 T cell memory alters the immune profile in enhanced HLH without.
Natural processing and presentation of the HOM-MEL-40/SSX2-derived p peptide. Natural processing and presentation of the HOM-MEL-40/SSX2-derived.
Specificity of HOM-MEL-40/SSX2 p stimulated CD8+ T-cells.
Cytotoxicity of p5399–107-induced CTL cells.
NY-ESO-1-specific cytotoxic reactivity of CD4+ T cell clones.
A2/Melan-A multimer+ CD8+ allorestricted CTL clones derived from donor DR fail to significantly recognize DR self-targets. A2/Melan-A multimer+ CD8+ allorestricted.
Increased levels of inflammation in mo-DCs translate into higher numbers of specific CD8 T-cell responses. Increased levels of inflammation in mo-DCs translate.
Functional characterization of polyclonal Melan-A monospecific allorestricted CTLs. (A) Recognition of Melan-A peptides by the polyclonal Melan-A monospecific.
HLA-A*0201 restriction of SSX2-derived p stimulated CD8+ T-cells.
Cytofluorometry analysis demonstrating the specific coating of anti-tumor Fab-HLA-A2/Flu conjugates on the surface of HLA-A2 negative tumor target cells,
Cytotoxic activity of CD8+ T-cells stimulated with SSX2-derived p
Representative cytokine and cytotoxicity responses to CMV peptides on day 0 and day 7 in one HLA A2+ donor. Representative cytokine and cytotoxicity responses.
PAP- and PA2024-specific CTLs at week 0 (prior to sipuleucel-T infusion) and at weeks 6 and 26 post–sipuleucel-T treatment. PAP- and PA2024-specific CTLs.
MDSC-derived IL-6 enhances tumor progression through the inhibition of tumor-specific TH1 development and of their helper activity for CD8+ T cells. MDSC-derived.
Serum IFNγ and immune responses following tecemotide/cisplatin combination treatment in a urethane-induced hMUC1.Tg lung cancer mouse model. Serum IFNγ.
LSECtin, expressed by B16 cells, inhibits the tumor-specific immune responses both in vivo and in vitro. LSECtin, expressed by B16 cells, inhibits the.
Vaccination schedule. Vaccination schedule. Vaccinations were given in cycles; each cycle consisted of four injections (vertical lines). Up to four additional.
Induction of NY-ESO-1-specific CD4+ and CD8+ T cell responses after in vitro presensitization with NY-ESO-1 p or Ad2/ESO. Induction of NY-ESO-1-specific.
Location and modification of potential target peptides within PASD1.
Design and operation of p.DOM-epitope vaccines.
Human monoclonal anti-NY-ESO-1 antibody (12D7) facilitates cross-presentation of a NY-ESO-1-derived, HLA-A2-restriced epitope (NY-ESO-1157–165). Human.
Presentation transcript:

Specific recognition of HOM-MEL-40/SSX2-derived p103-111 pulsed targets by p103-111 stimulated T-cells from patients with HOM-MEL-40/SSX2 positive breast cancers (A) and HLA-A*0201 positive healthy controls (B). Specific recognition of HOM-MEL-40/SSX2-derived p103-111 pulsed targets by p103-111 stimulated T-cells from patients with HOM-MEL-40/SSX2 positive breast cancers (A) and HLA-A*0201 positive healthy controls (B). IFN-gamma production was measured by ELISPOT assay, as determined after three weeks of stimulation (i.e. after sensitization with peptide on days 1, 7 and 14). An HLA-A*02 binding, but non-immunogenic peptide from human helicase (p148-156) served as a negative control. The numbers of IFN-gamma spots per 25,000 T-cells arising from a reaction against target cells and SSX2 p103-111 (black), as well as against target cells and control peptide (white), are shown for each donor. Claudia Wagner et al. Cancer Immun 2003;3:18 Copyright © 2003 by Michael Pfreundschuh